Infection-control report cards--securing patient safety.

Advocates of public reporting have been spurred on by the occurrence of nosocomial infections in 5 to 10 percent of hospitalized patients. Drs. Robert Weinstein, Jane Siegel, and P.J. Brennan write that report cards assessing nosocomial infections will require interdisciplinary collaboration, a greater commitment of resources to infection-prevention practices, and conspicuous inclusion of these efforts in patient-safety programs.

[1]  H. Sigstad.  A clinical diagnostic index in the diagnosis of the dumping syndrome. Changes in plasma volume and blood sugar after a test meal. , 2009, Acta medica Scandinavica.

[2]  R. Mansel,et al.  Benign breast disorders. , 2005, The New England journal of medicine.

[3]  D. Cardo,et al.  Guidance on public reporting of healthcare-associated infections: recommendations of the Healthcare Infection Control Practices Advisory Committee. , 2005, American journal of infection control.

[4]  R. Mansel,et al.  European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia. , 2004, American journal of obstetrics and gynecology.

[5]  John Simes,et al.  Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease , 2004, Circulation.

[6]  D. Drucker,et al.  Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. , 2004, Endocrinology.

[7]  R. Steinbrook.  Surgery for severe obesity. , 2004, The New England journal of medicine.

[8]  Cynthia A Afshari,et al.  Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX-2, promoting a premalignant program. , 2004, Cancer cell.

[9]  J. Manson,et al.  The escalating pandemics of obesity and sedentary lifestyle. A call to action for clinicians. , 2004, Archives of internal medicine.

[10]  H. Noushmehr,et al.  Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. , 2003, Endocrinology.

[11]  R. Langer,et al.  Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. , 2003, JAMA.

[12]  Alfons G H Kessels,et al.  The additional diagnostic value of ultrasonography in the diagnosis of breast cancer. , 2003, Archives of internal medicine.

[13]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[14]  R. Brolin,et al.  Bariatric Surgery for Morbid Obesity , 2003 .

[15]  M. Shetty,et al.  Prospective Evaluation of the Value of Combined Mammographic and Sonographic Assessment in Patients With Palpable Abnormalities of the Breast , 2003, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[16]  D. Drucker,et al.  Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. , 2003, Diabetes.

[17]  J Cuzick,et al.  Overview of the main outcomes in breast-cancer prevention trials , 2003, The Lancet.

[18]  W. Dupont,et al.  Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study , 2003, The Lancet.

[19]  J. Webster,et al.  Hyperprolactinemia: Etiology, Diagnosis, and Management , 2002, Seminars in reproductive medicine.

[20]  D. Kuik,et al.  Evening primrose oil and fish oil for severe chronic mastalgia: a randomized, double-blind, controlled trial. , 2002, American journal of obstetrics and gynecology.

[21]  E. Halpern,et al.  Specificity of mammography and US in the evaluation of a palpable abnormality: retrospective review. , 2002, Radiology.

[22]  David Tritchler,et al.  Heritability of mammographic density, a risk factor for breast cancer. , 2002, The New England journal of medicine.

[23]  M Baum,et al.  First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial , 2002, The Lancet.

[24]  S. Cummings,et al.  American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  F. Dirbas,et al.  Clinical Management of Breast Pain: A Review , 2002, Obstetrical & gynecological survey.

[26]  T. Key,et al.  Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. , 2002, Journal of the National Cancer Institute.

[27]  K. Mokbel,et al.  The Evolving Role of Mammary Ductoscopy , 2002, Current medical research and opinion.

[28]  S. Schnitt.  Benign breast disease and breast cancer risk: potential role for antiestrogens. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  B. Ljung,et al.  Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. , 2001, Journal of the National Cancer Institute.

[30]  M S Soo,et al.  Negative predictive value of sonography with mammography in patients with palpable breast lesions. , 2001, AJR. American journal of roentgenology.

[31]  J. Holst,et al.  Postprandial GLP-1, Norepinephrine, and Reactive Hypoglycemia in Dumping Syndrome , 2001, Digestive Diseases and Sciences.

[32]  M. Levine,et al.  Chemoprevention of breast cancer: A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer , 2001 .

[33]  D. Bowen,et al.  Comparisons of two breast cancer risk estimates in women with a family history of breast cancer. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[34]  Navin Parekh,et al.  Effects of mammographic density and benign breast disease on breast cancer risk (United States) , 2001, Cancer Causes & Control.

[35]  T. Rohan,et al.  Cyclin D1 protein overexpression and gene amplification in benign breast tissue and breast cancer risk , 2001, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[36]  R. Lloyd,et al.  Noninsulinoma pancreatogenous hypoglycemia syndrome: an update in 10 surgically treated patients. , 2000, Surgery.

[37]  H. Ozçelik,et al.  p53 protein accumulation and mutations in normal and benign breast tissue , 2000, International journal of cancer.

[38]  F. Magni,et al.  Identification of sulfonylureas in serum by electrospray mass spectrometry. , 2000, Analytical biochemistry.

[39]  A. Miller,et al.  Mammographic densities and the prevalence and incidence of histological types of benign breast disease , 2000, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[40]  M H Gail,et al.  Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. , 1999, Journal of the National Cancer Institute.

[41]  M. Somerfield,et al.  American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  S. Zylstra.  Office management of benign breast disease. , 1999, Clinical obstetrics and gynecology.

[43]  A. Terzic,et al.  Noninsulinoma pancreatogenous hypoglycemia: a novel syndrome of hyperinsulinemic hypoglycemia in adults independent of mutations in Kir6.2 and SUR1 genes. , 1999, The Journal of clinical endocrinology and metabolism.

[44]  D. Henson,et al.  Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. , 1998, Archives of pathology & laboratory medicine.

[45]  N. Boyd,et al.  Mammographic densities and breast cancer risk. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[46]  A. Miller,et al.  Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. , 1998, Journal of the National Cancer Institute.

[47]  J. Manson,et al.  Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. , 1998, Journal of the National Cancer Institute.

[48]  J. Elmore,et al.  Ten-year risk of false positive screening mammograms and clinical breast examinations. , 1998, The New England journal of medicine.

[49]  J. L. Rodriguez,et al.  Mastalgia: Tailoring treatment to type of breast pain , 1997 .

[50]  D. Ader,et al.  Prevalence and impact of cyclic mastalgia in a United States clinic-based sample. , 1997, American journal of obstetrics and gynecology.

[51]  R. Foster,et al.  Breast cancer surgical practice guidelines. Society of Surgical Oncology practice guidelines. , 1997, Oncology.

[52]  G. Colditz,et al.  Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[53]  P. Goodwin,et al.  Breast health and associated premenstrual symptoms in women with severe cyclic mastopathy. , 1997, American journal of obstetrics and gynecology.

[54]  S. Cummings,et al.  Sex steroid hormones, bone mineral density, and risk of breast cancer. , 1997, Environmental health perspectives.

[55]  A. Groves,et al.  An audit of cytology in the evaluation of nipple discharge. A retrospective study of 10 years' experience , 1996 .

[56]  S. Ciatto,et al.  [The role of ductal galactography in the differential diagnosis of breast carcinoma]. , 1996, La Radiologia medica.

[57]  W D Plummer,et al.  Long-term risk of breast cancer in women with fibroadenoma. , 1994, The New England journal of medicine.

[58]  N. Wetzig.  Mastalgia: a 3 year Australian study. , 1994, The Australian and New Zealand journal of surgery.

[59]  G. Contesso,et al.  Oral contraceptive use and risk of benign breast disease in a French case-control study of young women. , 1993, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[60]  S J Schnitt,et al.  Benign breast disease resolved and unresolved issues , 1993, Cancer.

[61]  L. Brinton,et al.  Breast cancer risk associated with proliferative breast disease and atypical hyperplasia , 1993, Cancer.

[62]  R. Taylor,et al.  C-peptide immunochemiluminometric assay developed from two seemingly identical polyclonal antisera. , 1992, Annals of clinical and laboratory science.

[63]  R. Hiatt,et al.  Risk of breast cancer after benign breast diseases. Variation by histologic type, degree of atypia, age at biopsy, and length of follow-up. , 1992, American journal of epidemiology.

[64]  G. Colditz,et al.  A prospective study of benign breast disease and the risk of breast cancer , 1992, JAMA.

[65]  R. Mansel,et al.  Drug Treatments for Mastalgia: 17 Years Experience in the Cardiff Mastalgia Clinic , 1992, Journal of the Royal Society of Medicine.

[66]  J. Holst,et al.  Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy , 1991, Digestive Diseases and Sciences.

[67]  I. Fentiman,et al.  LHRH analogue for treatment of recurrent and refractory mastalgia. , 1990, Annals of the Royal College of Surgeons of England.

[68]  M. Gail,et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.

[69]  W. Dupont,et al.  Invasive breast cancer risk in women with sclerosing adenosis , 1989, Cancer.

[70]  N. Boyd,et al.  Cyclical mastopathy: A critical review of therapy , 1988, The British journal of surgery.

[71]  P. Taylor,et al.  A prospective study of the development of breast cancer in 16,692 women with benign breast disease. , 1988, American journal of epidemiology.

[72]  I. Messinis,et al.  Treatment of Premenstrual Mastalgia with Tamoxifen , 1988, Acta obstetricia et gynecologica Scandinavica.

[73]  J. Wolfe,et al.  Mammographic parenchymal patterns and quantitative evaluation of mammographic densities: a case-control study. , 1987, AJR. American journal of roentgenology.

[74]  W. Dupont,et al.  Breast cancer risk associated with proliferative disease, age at first birth, and a family history of breast cancer. , 1987, American journal of epidemiology.

[75]  J. Hannan,et al.  Introduction to probability and mathematical statistics , 1986 .

[76]  W. Dupont,et al.  Atypical hyperplastic lesions of the female breast: A long-term follow-up study , 1986 .

[77]  I. Fentiman,et al.  DOUBLE-BLIND CONTROLLED TRIAL OF TAMOXIFEN THERAPY FOR MASTALGIA , 1986, The Lancet.

[78]  W D Dupont,et al.  Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.

[79]  Tighe,et al.  Therapeutic value of a supporting brassière in mastodynia. , 1976, British medical journal.

[80]  Steigelman Kt.  Tumors of the pancreas. , 1951, The Journal of the American Osteopathic Association.

[81]  J. Bragg-Gresham,et al.  HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[82]  W. Coutinho,et al.  Insulinoma Misdiagnosed as Dumping Syndrome after Bariatric Surgery , 2004, Obesity surgery.

[83]  S. Falkenberry.  Nipple discharge. , 2002, Obstetrics and gynecology clinics of North America.

[84]  P. O'brien,et al.  Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danazol. , 1999, American journal of obstetrics and gynecology.

[85]  F. Service.  Classification of hypoglycemic disorders. , 1999, Endocrinology and metabolism clinics of North America.

[86]  B. Scheithauer,et al.  The immunophenotype of pituitary adenomas , 1996, Endocrine pathology.

[87]  L. Perloff,et al.  The significance of age in patients with nipple discharge. , 1970, Surgery, gynecology & obstetrics.